TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)
Launched by ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION · May 13, 2019
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
This pre-post quasi-experimental evaluation study will be conducted in ten countries involved in the Catalyzing Pediatric TB Innovation (CaP-TB) project: Cameroon, Cote D'Ivoire, Democratic Republic of Congo, Kenya, Lesotho, Malawi, Tanzania, Uganda, Zimbabwe and India. The CaP-TB project is a project designed to use innovative methods and capacity building to strengthen the health systems of developing countries in terms of pediatric TB case detection, early accurate diagnosis and effective treatment. This project is funded by Unitaid headquartered in Geneva, Switzerland and is implemented...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB screening (including screening, diagnosis and treatment for active TB, and provision of TB preventive therapy).
- • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB diagnosis
- • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB treatment for active TB
- • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB preventive therapy
- Exclusion Criteria:
- • • All pediatric TB patients who enter CaP TB project site in any of the 10 countries and who are above 15 years old
About Elizabeth Glaser Pediatric Aids Foundation
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a leading nonprofit organization dedicated to eradicating pediatric HIV/AIDS through innovative research, comprehensive care, and advocacy. Founded in 1988, EGPAF focuses on improving the health and well-being of children and families affected by HIV/AIDS worldwide. Through its commitment to advancing scientific knowledge and implementing evidence-based interventions, the foundation plays a pivotal role in clinical trials aimed at developing effective treatments and prevention strategies. By collaborating with global health partners, EGPAF strives to ensure that every child has the opportunity to live a healthy, HIV-free life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Djoungolo, , Cameroon
Kinshasa, , Congo, The Democratic Republic Of The
Abidjan, , Côte D'ivoire
Hyderabad, , India
Nairobi, , Kenya
Maseru, , Lesotho
Dedza, , Malawi
Singida, , Tanzania
Mbarara, , Uganda
Harare, , Zimbabwe
Patients applied
Trial Officials
Jennifer Cohn, MD
Principal Investigator
Elizabeth Glaser Pediatric AIDS Foundation
Martina Casenghi, PhD
Principal Investigator
Elizabeth Glaser Pediatric AIDS Foundation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials